Sangui BioTech International Inc. / Key word(s): Final Results
25.09.2014 / 12:00
SanguiBioTech: Revenues attain USD 133,000 in financial year 2014
Witten, Germany, September 25, 2014
For its financial year 2014 (ended June 30, 2014) Sangui BioTech International, Inc. reports revenues from product sales and royalties in the amount of USD133,470 USD after USD105,487 in the previous financial year. This increase is primarily attributable to royalties on sales of the Granulox wound dressing, marketing and sales of which are out-licensed to SastoMed GmbH, a joint venture company in which Sangui holds a stake of 25%. Revenues in the fourth quarter of the 2014 financial year came in at USD43,729 USD (Q4/2013: USD24,056). Granulox is the first dressing to significantly improve oxygen supply to wounds with poor blood supply and thereby decisively accelerates wound healing.
Research and development expenses increased to USD543,071 (FY 2013: USD65,010). The position includes the purchase of a comprehensive set of clinical data. This also led to the increase of total operating expenses to USD1.4 million (FY 2013: USD1.3 million). The net result attributable to shareholders amounts to minus USD1.4 million up from minus USD2.1 million in the previous financial year when an impairment of receivables in the amount of USD1.0 million had occurred which had been brought in as capital into SastoMed GmbH. Cash outflow from operations in the amount of USD0.8 million (FY 2013: USD0.8 million) and from investing activities in the amount of USD0.2million (FY 2013: USD0,9 million) were offset by an cash inflow from financing of USD0.9 million (FY 2013: USD1.4 million).
Sangui BioTech International, Inc. ("SGBI") is a holding company the shares of which are being traded on the OTCQB marketplace (www.otcmarkets.com: SGBI) and the OTC markets of Berlin and Hamburg-Hannover stock exchanges. Its purpose is to provide financing and access to the capital markets for the enterprises of the Sangui group. SanguiBioTech GmbH is a ninety percent subsidiary of Sangui BioTech International, Inc.
For more information please contact:
Joachim Fleing
Phone: +49 (179) 7963472
Fax: +49 (2302) 915191
e-mail: fleing@sangui.de